SkinHealth Systems reported third quarter 2026 results that exceeded analyst estimates on both the top and bottom lines. The performance was characterized by a return to growth in the high-margin consumables segment, which helped mitigate continued pressure on capital equipment placements. Management highlighted improved operational efficiency and the successful retirement of debt as key steps in stabilizing the business model.
Key Highlights
- Net sales of $69.2 million beat the consensus estimate of $67.97 million, supported by $50.4 million in consumables revenue.
- Net loss narrowed significantly to $(0.9) million, or $(0.14) per share, outperforming the expected loss of $(1.32) per share.
- Adjusted EBITDA grew to $13.4 million, representing a 19.3% margin, compared to $8.9 million in the prior year period.
- The company retired its remaining 2026 debt, totaling $103.2 million in principal, ending the quarter with $112 million in cash.
- Delivery system placements declined to 798 units from 875 in the prior year, reflecting continued macroeconomic headwinds for capital equipment.